Journal articles: 'Stiripentol'

1

&NA;. "Stiripentol." Drugs in R & D 3, no. 3 (2002): 220–22. http://dx.doi.org/10.2165/00126839-200203030-00019.

APA, Harvard, Vancouver, ISO, and other styles

2

Toffoli, P., J. C. Rouland, N. Rodier, R. Ceolin, F. Lepage, and J. Astoin. "Stiripentol." Acta Crystallographica Section C Crystal Structure Communications 44, no. 12 (December 15, 1988): 2212–14. http://dx.doi.org/10.1107/s0108270188008613.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chiron, Catherine. "Stiripentol." Expert Opinion on Investigational Drugs 14, no. 7 (July 2005): 905–11. http://dx.doi.org/10.1517/13543784.14.7.905.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Chiron, Catherine. "Stiripentol." Neurotherapeutics 4, no. 1 (January 2007): 123–25. http://dx.doi.org/10.1016/j.nurt.2006.10.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Plosker, Greg L. "Stiripentol." CNS Drugs 26, no. 11 (September 26, 2012): 993–1001. http://dx.doi.org/10.1007/s40263-012-0004-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kashid, Santosh Kumar, Amit Tapkir, and Pravin Choudhari. "ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR STABILITY INDICATING HPTLC METHOD FOR ASSAY OF STIRIPENTOL IN BULK AND DOSAGE FORM." Journal of Applied Pharmaceutical Sciences and Research 3, no. 4 (January 25, 2021): 26–30. http://dx.doi.org/10.31069/japsr.v3i4.5.

Full text

Abstract:

Introduction: This work is concerned with the stability-indicating method development and validation of Stiripentol in a bulk drug and formulation by high-performance thin-layer chromatographic method (HPTLC). Materials and Methods:The pre-coated silica gel 60 F254 aluminum plate was selected as the stationary phase, and the solvent system consisted of Ethyl acetate: Dichloromethane: Toluene (2:2:6 v/v) used as developing solvents. Analysis of Stiripentol was carried out at 301 nm with Stiripentol being detected at an R(f) of 0.63. The developed method was validated for linearity, accuracy, precision, limit of detection (LoD), limit of quantitation (LoQ), robustness parameters, and stability are determined by force degradation study. Results and Discussion: The correlation coefficient of Stiripentol was 0.994 observed. The calibration plot was linear between 50–300 ng/band, respectively. The average percentage recovery of Stiripentol was found to be 100.25 %. Intra and inter-day precision measured as %RSD was less than 2%. Hence stability study of Stiripentol, it was found to degrade in acidic condition(8.52% - 0.1N HCL for 30 minutes at room temperature), alkali condition(7.47%- 0.1 N NaOH for 30min at room temperature), Hydrolytic condition(4.73%– dist. Water for 30min at room temperature), thermal condition(7.69%-40°C for 30min ), oxidative condition(7.55% - 3% H2O2 for 30min at room temperature) and photolytic UV condition(7.54% -24hr UV radiation) respectively. Stiripentol was unstable in acidic condition and stable in normal dist. Water hydrolytic condition. Conclusion: The proposed method was found to be very sensitive and accurate for the determination of Stiripentol in bulk and formulation.

APA, Harvard, Vancouver, ISO, and other styles

7

Matuszewska, Agnieszka, Beata Nowak, Anna Nikodem, Anna Merwid-Ląd, Benita Wiatrak, Tomasz Tomkalski, Diana Jędrzejuk, et al. "Antiepileptic Stiripentol May Influence Bones." International Journal of Molecular Sciences 22, no. 13 (July 2, 2021): 7162. http://dx.doi.org/10.3390/ijms22137162.

Full text

Abstract:

Bone structure abnormalities are increasingly observed in patients chronically treated with antiepileptic drugs (AEDs). The majority of the available data concern older conventional AEDs, while the amount of information regarding newer AEDs, including stiripentol, is limited. The aim of the study was to assess the effect of stiripentol on bones. For 24 weeks, male Wistar rats, received 0.9% sodium chloride (control group) or stiripentol (200 mg/kg/day) (STP group). In the 16th week of the study, we detected lower serum PINP levels in the STP group compared to the control group. In the 24th week, a statistically significant lower 1,25-dihydroxyvitamin D3 level, higher inorganic phosphate level and higher neutrophil gelatinase-associated lipocalin (NGAL) levels in serum were found in the STP group compared to the control. Micro X-ray computed tomography of the tibias demonstrated lower bone volume fraction, lower trabecular thickness, higher trabecular pattern factor and a higher structure model index in the stiripentol group. Considering the results of this experiment on rats which suggests that long-term administration of stiripentol may impair the cancellous bone microarchitecture, further prospective human studies seem to be justified. However, monitoring plasma vitamin D, calcium, inorganic phosphate and kidney function in patients on long-term stiripentol therapy may be suggested.

APA, Harvard, Vancouver, ISO, and other styles

8

Buck, Marcia L., and Howard P. Goodkin. "Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome." Annals of Pharmacotherapy 53, no. 11 (June 6, 2019): 1136–44. http://dx.doi.org/10.1177/1060028019856008.

Full text

Abstract:

Objective: To describe the pharmacology, efficacy, and safety of stiripentol in the treatment of refractory seizures in patients with Dravet syndrome. Data Sources: A search of the English language literature was conducted using PubMed and MEDLINE (1978 to April 2019) with the search terms stiripentol, Dravet syndrome, and refractory epilepsy. Other resources included article bibliographies, prescribing information, and relevant trials at https://clinicaltrials.gov/ . Study Selection and Data Extraction: All phase 1, 2, or 3 trials; observational studies; and retrospective studies were analyzed. Data Synthesis: In controlled studies, stiripentol has been shown to reduce seizure frequency by 50% or more in 40% to 70% of patients with Dravet syndrome. Reductions in seizure duration and episodes of status epilepticus have also been documented. Common adverse effects include somnolence and anorexia. Stiripentol inhibits the metabolism of clobazam and valproate, often requiring dose adjustment. Relevance to Patient Care and Clinical Practice: Stiripentol, a direct allosteric modulator of GABAA receptors, offers a novel approach to treatment in patients with Dravet syndrome, both with and without pathogenic variants of the sodium channel α-1 subunit gene, and potentially other refractory seizures. Although available outside the United States for a decade, it was only recently approved by the Food and Drug Administration for patients 2 years of age and older with Dravet syndrome taking clobazam. Conclusions: Stiripentol is an effective adjunctive therapy for reducing the frequency and duration of refractory seizures in patients with Dravet syndrome. Its role in the treatment of other refractory epilepsies requires further study.

APA, Harvard, Vancouver, ISO, and other styles

9

Darwish, Hany W., Ali S. Abdelhameed, Mohamed I. Attia, Ahmed H. Bakheit, Nasr Y. Khalil, and Abdulrahman A. Al-Majed. "A Stability-Indicating HPLC-DAD Method for Determination of Stiripentol: Development, Validation, Kinetics, Structure Elucidation and Application to Commercial Dosage Form." Journal of Analytical Methods in Chemistry 2014 (2014): 1–10. http://dx.doi.org/10.1155/2014/638951.

Full text

Abstract:

A rapid, simple, sensitive, and accurate isocratic reversed-phase stability-indicating high performance liquid chromatography method has been developed and validated for the determination of stiripentol and its degradation product in its bulk form and pharmaceutical dosage form. Chromatographic separation was achieved on a Symmetry C18 column and quantification was achieved using photodiode array detector (DAD). The method was validated in accordance with the ICH requirements showing specificity, linearity (r2=0.9996, range of 1–25 μg/mL), precision (relative standard deviation lower than 2%), accuracy (mean recovery100.08±1.73), limits of detection and quantitation (LOD = 0.024 and LOQ = 0.081 μg/mL), and robustness. Stiripentol was subjected to various stress conditions and it has shown marked stability under alkaline hydrolytic stress conditions, thermal, oxidative, and photolytic conditions. Stiripentol degraded only under acidic conditions, forming a single degradation product which was well resolved from the pure drug with significantly different retention time values. This degradation product was characterized by1H-NMR and13C-NMR spectroscopy as well as ion trap mass spectrometry. The results demonstrated that the method would have a great value when applied in quality control and stability studies for stiripentol.

APA, Harvard, Vancouver, ISO, and other styles

10

Landgraf, M., S. Syrbe, A. Merkenschlager, and M. K. Bernhard. "Stiripentol, Eslicarbazepinacetat & Co." Kinder- und Jugendmedizin 10, no. 04 (2010): 234–37. http://dx.doi.org/10.1055/s-0038-1628979.

Full text

Abstract:

ZusammenfassungIn den vergangenen sechs Jahren wurden in Deutschland sechs neue Antikonvulsiva zugelassen: Pregabalin, Rufinamid, Zonisamid, Lacosamid, Stiripentol und Eslicarbazepin-acetat. Teilweise handelt es sich um Substanzen, die über neue Mechanismen ihre erregungshemmende Wirkung entfalten, teilweise um die Weiterentwicklung bestehender Antikonvulsiva. Diese neuen Medikamente sind bislang entweder nur bei Erwachsenen oder als sogenannte Orphan Drugs nur sehr eingeschränkt zugelassen.Im Folgenden werden die genannten neuen Antikonvulsiva hinsichtlich ihrer Zulassungen, Wirkmechanismen und Nebenwirkungsprofile kurz charakterisiert. Die vor allem für Kinder und Jugendliche relevanten bisherigen Studiendaten werden genannt.Diese neuesten Antikonvulsiva dürften vor allem als Zusatztherapie auch in der Pädiatrie künftig vielversprechende Therapieoptionen bieten.

APA, Harvard, Vancouver, ISO, and other styles

11

Sudrik, Vilas, Arjun Bodkhe, Dnyaneshwar Karpe, and Shamrao Lawande. "A Facile One-pot Process for the Synthesis of Stiripentol." Oriental Journal Of Chemistry 38, no. 6 (December 30, 2022): 1414–18. http://dx.doi.org/10.13005/ojc/380611.

Full text

Abstract:

A facile one-pot synthesis of Stiripentol (STP) 1 in which Initially 3, 4-dihydroxy benzaldehyde 13 is treated with methylene diiodide using base KOH to get 2 which undergoes in situ Knoevenagel condensation with 3,3-dimethyl 2-butanone using catalytic Phase Transfer Catalyst i.e. Tetrabutylammonium bromide (TBAB) and K2CO3 to get 4 which undergo Regioselective Luche reduction of α-β unsaturated ketone with NaBH4 and Cerium (III) chloride (CeCl3) to get pure Stiripentol 1 which is commercially viable and eco-friendly.

APA, Harvard, Vancouver, ISO, and other styles

12

Kerr, Bradley M., Juan M. Martinez-Lage, C. Viteri, Jacques Tor, A. Craig Eddy, and René H. Levy. "Carbamazepine Dose Requirements During Stiripentol Therapy: Influence of Cytochrome P-450 Inhibition Stiripentol." Epilepsia 32, no. 2 (April 1991): 267–74. http://dx.doi.org/10.1111/j.1528-1157.1991.tb05254.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Verdier, Marie-Clémence, Olivier Tribut, and Danièle Bentué-Ferrer. "Suivi thérapeutique pharmacologique du stiripentol." Therapies 67, no. 2 (March 2012): 157–60. http://dx.doi.org/10.2515/therapie/2012014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Grosenbaugh, Denise K., and David D. Mott. "Stiripentol in refractory status epilepticus." Epilepsia 54 (September 2013): 103–5. http://dx.doi.org/10.1111/epi.12291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

REY, E., V. JULLIEN, J. VINCENT, and G. PONS. "Is pharmacokinetics of stiripentol linear?" Clinical Pharmacology & Therapeutics 77, no. 2 (February 2005): P64. http://dx.doi.org/10.1016/j.clpt.2004.12.134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

El-behairy, Mohammed Farrag, and Hanan Naeim Hafez Attia. "DESIGN, SYNTHESIS AND ANTICONVULSANT PROFILE OF 5-(BENZO [D][1,3]DIOXOL-5-YL)-3-TERT-BUTYL-4, 5-DIHYDROPYRAZOLE DERIVATIVES." International Journal of Pharmacy and Pharmaceutical Sciences 9, no. 6 (June 1, 2017): 180. http://dx.doi.org/10.22159/ijpps.2017v9i6.17520.

Full text

Abstract:

Objective: Utilisation of the ligand-based design and molecular hybridization to design promising candidates with prospective efficacy and safety. Synthesis of the designed candidates using different synthetic methods. Biological evaluation of the newly synthesised candidates as anticonvulsant agents.Methods: Three novel series of 5-(benzo[d][1,3]dioxol-5-yl)-3-tert-butyl-4,5-dihydropyrazoles have been designed via ligand-based drug discovery and molecular hybridization. Proper synthetic routes have been followed in the preparation of compounds (2-23) which have been characterised by different spectral techniques. Antiepileptic potential was assessed by biological evaluation using ‘classical’ animal models of epilepsy, in addition to rotarod test for toxicity.Results: 4-Nitrophenyl derivatives (5, 13, and19) displayed the highest potency. Compound 5was the most active substituent in series A (N'-aroyl-3-tert-butyl-4,5-dihydro-1H-pyrazole-1-carbohydrazide). It was 2.7 and 1.3 times more active than reference drug Stiripentol (I) and lead compound III, respectively. Compound13 was the best candidate in series B (N'-arylidene-3-tert-butyl-4,5-dihydro-1H-pyrazole-1-carbohydrazide). It was 3.3, 1.5, and 1.2 times more potent than Stiripentol, lead compound III and new compound 5, respectively. Two members (19 and 21) of series C (1,3,4-oxadiazole derivatives) achieved 100 % protection at lower doses than I and III, being 2.6 and 2.4 times more active than Stiripentol. In scPTZ screen, the most active congeners (5, 13, 19) exhibited ED50 values of 45, 48, and 81 mg/kg, respectively, which are highly superior as compared to that of reference drug Stiripentol(I) and lead compound III (ED50 115 and 110 mg/kg, respectively).Conclusion: Ligand-based design together with molecular hybridization in drug design succeeded to produce potent and wide spectrum candidates.

APA, Harvard, Vancouver, ISO, and other styles

17

Frampton, James E. "Stiripentol: A Review in Dravet Syndrome." Drugs 79, no. 16 (October 15, 2019): 1785–96. http://dx.doi.org/10.1007/s40265-019-01204-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Nickels, Katherine C., and Elaine C. Wirrell. "Stiripentol in the Management of Epilepsy." CNS Drugs 31, no. 5 (April 22, 2017): 405–16. http://dx.doi.org/10.1007/s40263-017-0432-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Add-on stiripentol promising in paediatric epilepsy." Inpharma Weekly &NA;, no. 1217 (December 1999): 8. http://dx.doi.org/10.2165/00128413-199912170-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Letavernier, Emmanuel, and Michel Daudon. "Effet du stiripentol sur l’excrétion urinaire d’oxalate." Néphrologie & Thérapeutique 17 (April 2021): S95—S99. http://dx.doi.org/10.1016/j.nephro.2020.02.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Czuczwar, Stanislaw J., Michal K. Trojnar, Aleksandra Gergont, Slawomir Kroczka, and Marek Kacinski. "Stiripentol – characteristic of a new antiepileptic drug." Expert Opinion on Drug Discovery 3, no. 4 (March 26, 2008): 453–60. http://dx.doi.org/10.1517/17460441.3.4.453.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Trabs, Nicole, Mathias Trabs, Stefan Stodieck, and Patrick M. House. "Influence of stiripentol on perampanel serum levels." Epilepsy Research 164 (August 2020): 106367. http://dx.doi.org/10.1016/j.eplepsyres.2020.106367.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Fisher, Janet L. "The effects of stiripentol on GABAA receptors." Epilepsia 52 (April 2011): 76–78. http://dx.doi.org/10.1111/j.1528-1167.2011.03008.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Peigné, Sophie, Stéphanie Chhun, Michel Tod, Elisabeth Rey, Christelle Rodrigues, Catherine Chiron, Gérard Pons, and Vincent Jullien. "Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy." Clinical Pharmacokinetics 57, no. 6 (August 17, 2017): 739–48. http://dx.doi.org/10.1007/s40262-017-0592-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Shi, Xue-Min, Wen-Yan She, Ting-Ting Liu, Lian-Xun Gao, Yu-Jiao Liu, and Yi Liu. "1,3-Benzodioxole Derivatives Improve the Anti-Tumor Efficiency of Arsenicals." International Journal of Molecular Sciences 23, no. 13 (June 22, 2022): 6930. http://dx.doi.org/10.3390/ijms23136930.

Full text

Abstract:

Arsenicals have been widely used in the treatment of cancers such as leukemia and other tumors. However, their side effects limit their clinical application. Stiripentol, a second-line adjunctive treatment for epilepsy with a good safety profile, inhibits microsomal cytochrome-P450-family enzymes to extend the retention time of co-administration. Inspired by the metabolism of stiripentol, the 1,3-benzodioxole responsible for the inhibition and its metabolic derivatives were conjugated with arsenical precursors. The fabricated arsenicals were eliminated much slower in mice and maintained an efficient concentration in the blood for a longer time than that of the arsenical precursors. They also performed better in anti-proliferation by inhibiting the thioredoxin system to induce oxidative stress, and concomitantly to initiate apoptosis in vitro and in vivo. The fabricated arsenicals reversed the hemogram of tumor-bearing mice to normal and eliminated the tumor without causing damage to any organs, exhibiting a good design strategy and pre-clinical application for leukemia and other tumors.

APA, Harvard, Vancouver, ISO, and other styles

26

Schubert-Bast, Susanne, and Adam Strzelczyk. "Neue Aspekte zur Therapie des Dravet-Syndroms." Kinder- und Jugendmedizin 22, no. 05 (November 2022): 324–32. http://dx.doi.org/10.1055/a-1908-5561.

Full text

Abstract:

ZUSAMMENFASSUNGDas Dravet-Syndrom ist gekennzeichnet durch eine schwer behandelbare Epilepsie und assoziierte Komorbiditäten. Nun stehen neben Stiripentol mit Cannabidiol und Fenfluramin zwei neue und spezifische Therapieoptionen zur Verfügung. In diesem Beitrag erfolgt ein Überblick über die gebräuchlichsten und neuen Antikonvulsiva, deren Wirkung, Sicherheitsprofil sowie die potenziellen Interaktionen.

APA, Harvard, Vancouver, ISO, and other styles

27

Kossoff, Eric. "Stiripentol for Dravet Syndrome: Is it Worth It?" Epilepsy Currents 14, no. 1 (January 2014): 22–23. http://dx.doi.org/10.5698/1535-7597-14.1.22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Letavernier, Emmanuel, and Michel Daudon. "Stiripentol identifies a therapeutic target to reduce oxaluria." Current Opinion in Nephrology & Hypertension 29, no. 4 (July 2020): 394–99. http://dx.doi.org/10.1097/mnh.0000000000000621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Peigné, Sophie, Elisabeth Rey, Marie-Emmanuelle Le Guern, Olivier Dulac, Catherine Chiron, Gerard Pons, and Vincent Jullien. "Reassessment of stiripentol pharmacokinetics in healthy adult volunteers." Epilepsy Research 108, no. 5 (July 2014): 909–16. http://dx.doi.org/10.1016/j.eplepsyres.2014.03.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Stiripentol effective in severe myoclonic epilepsy in infancy." Inpharma Weekly &NA;, no. 1264 (November 2000): 7. http://dx.doi.org/10.2165/00128413-200012640-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Perez, J., C. Chiron, C. Musial, E. Rey, H. Blehaut, P. d'Athis, J. Vincent, and O. Dulac. "Stiripentol: Efficacy and Tolerability in Children with Epilepsy." Epilepsia 40, no. 11 (November 1999): 1618–26. http://dx.doi.org/10.1111/j.1528-1157.1999.tb02048.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Kluger, G., and S. Arnold. "Neues aus der Pharmakotherapie." Nervenheilkunde 29, no. 04 (2010): 191–98. http://dx.doi.org/10.1055/s-0038-1628749.

Full text

Abstract:

ZusammenfassungRund ein Drittel aller Patienten mit fokaler Epilepsie ist trotz medikamentöser Behandlung nicht anfallsfrei (1). Insbesondere für diese Patienten mit schwer behandelbaren Epilepsien bieten medikamentöse Neuentwicklungen neue Chancen. Seit 2008 steht in Deutschland für Patienten mit fokaler Epilepsie mit Lacosamid ein Wirkstoff mit einem neuen Wirkungsmechanismus zur Verfügung. 2009 wurde die Medikamentenpalette um Eslicarbazepinacetat erweitert. Beide Substanzen haben in großen randomisierten Doppelblindstudien eine signifikante Reduktion der Anfallshäufigkeit im Vergleich zu Placebo belegen können. Zur Behandlung seltener Erkrankungen können Substanzen mit der Option des “Orphan- Drug”-Status auch nach Untersuchung vergleichsweise geringer Patientenzahlen unter besonderen Auflagen zur Verfügung gestellt werden. Als “Orphan Drug” zur Zusatzbehandlung des Lennox-Gastaut-Syndroms wurde 2007 Rufinamid von der EMEA zugelassen. Bereits seit 2001 ist Stiripentol als “Orphan Drug” von der EMEA zur Zusatzbehandlung des Dravet-Syndromes ausgewiesen und seit 2007 als “Orphan Drug” mit Auflagen für Europa zugelassen. 2008 konnte Stiripentol auch in Deutschland eingeführt werden. In dieser Übersicht sollen die wesentlichen Merkmale der genannten Substanzen dargestellt werden.Da selten auftretende Nebenwirkungen nach der Markteinführung einer Substanz auftreten können, sind weitere Untersuchungen notwendig,um die langfristige Sicherheit der vorgestellten Substanzen zu überprüfen.

APA, Harvard, Vancouver, ISO, and other styles

33

Vintan, Mihaela-Adela. "Should Off Label Antiepileptic Drugs Be Used for Treatment of Infancy and Childhood Epilepsy? Discussions Based on a Dravet Syndrome Case Report." Journal of Pediatric Epilepsy 9, no. 03 (May 28, 2020): 080–82. http://dx.doi.org/10.1055/s-0040-1712498.

Full text

Abstract:

AbstractEpilepsy represents a burdensome neurological disorder with higher incidence before the age of 18 years. The treatment is medical and involves long-term administration of antiepileptic drugs (AED). There are known high-resistant syndromes with onset in infancy and childhood, Dravet syndrome, being one of them. It is a well-known fact that early seizures treatment prevents associated comorbidities, cognitive and motor disabilities, and improve long-term prognosis. There are several AEDs available but not all of them are approved for use in infants. This is due to the need for additional toxicology studies at this age and for development of suitable formulations.A 14-month-old girl with Dravet syndrome was presented here. Prompt diagnosis was made based on clinical features and confirmed by the genetic tests. She partially responded to valproate and clobazam but continued to have prolonged febrile seizures. We added stiripentol after consulting reports of studies in infants younger than 2 years and after obtaining family consent. She responded well with decrease in episodes of status epilepticus and improvement in psychomotor development and stiripentol was tolerated well. Off label use of certain AEDs can benefit infants when there are no major pharmacokinetic differences in comparison to older children.

APA, Harvard, Vancouver, ISO, and other styles

34

Eschbach, Krista, and Kelly G. Knupp. "Stiripentol for the treatment of seizures in Dravet syndrome." Expert Review of Clinical Pharmacology 12, no. 5 (April 24, 2019): 379–88. http://dx.doi.org/10.1080/17512433.2019.1605904.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Strzelczyk, A., L. M. Kortland, S. Knake, and F. Rosenow. "Stiripentol for the treatment of super-refractory status epilepticus." Acta Neurologica Scandinavica 132, no. 6 (March 24, 2015): 435–39. http://dx.doi.org/10.1111/ane.12403.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Mount, C., N. Sharif, and D. Hindley. "G102(P) The role of stiripentol in intractable epilepsy." Archives of Disease in Childhood 101, Suppl 1 (April 2016): A58.2—A59. http://dx.doi.org/10.1136/archdischild-2016-310863.99.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Chiron, Catherine. "Long-term pragmatic use of stiripentol for Dravet syndrome." Developmental Medicine & Child Neurology 60, no. 6 (March 7, 2018): 535. http://dx.doi.org/10.1111/dmcn.13720.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

May, Theodor W., Rainer Boor, Thomas Mayer, Uwe Jürgens, Bernhard Rambeck, Nils Holert, Elisabeth Korn-Merker, and Christian Brandt. "Concentrations of Stiripentol in Children and Adults With Epilepsy." Therapeutic Drug Monitoring 34, no. 4 (August 2012): 390–97. http://dx.doi.org/10.1097/ftd.0b013e31825dc4a6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Mott, David D., Denise K. Grosenbaugh, and Janet L. Fisher. "Polytherapy with stiripentol: Consider more than just metabolic interactions." Epilepsy & Behavior 29, no. 3 (December 2013): 585. http://dx.doi.org/10.1016/j.yebeh.2013.09.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Inoue, Yushi, Yoko Ohtsuka, Hirokazu Oguni, Jun Tohyama, Hiroshi Baba, Katsuyuki Fukushima, Hideyuki Ohtani, Yukitoshi Takahashi, and Shunya Ikeda. "Stiripentol open study in Japanese patients with Dravet syndrome." Epilepsia 50, no. 11 (November 2009): 2362–68. http://dx.doi.org/10.1111/j.1528-1167.2009.02179.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Lockard, J. S., R. H. Levy, P. H. Rhodes, and D. F. Moore. "Stiripentol in Acute/Chronic Efficacy Tests in Monkey Model." Epilepsia 26, no. 6 (December 1985): 704–12. http://dx.doi.org/10.1111/j.1528-1157.1985.tb05715.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Lockard, Joan S., and Rene H. Levy. "Carbamazepine Plus Stiripentol: Is Poly therapy by Design Possible?" Epilepsia 29, no. 4 (August 1988): 476–81. http://dx.doi.org/10.1111/j.1528-1157.1988.tb03748.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Phillips, Nona K., and Joan S. Lockard. "Phenytoin and/or Stiripentol in Pregnancy: Infant Monkey Hyperexcitability." Epilepsia 34, no. 6 (November 1993): 1117–22. http://dx.doi.org/10.1111/j.1528-1157.1993.tb02143.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Céolin, R., J. Dugué, J. C. Rouland, C. Ralambosoa, and F. Lepage. "Solid state studies on stiripentol: a novel anticonvulsant drug." International Journal of Pharmaceutics 74, no. 1 (August 1991): 77–82. http://dx.doi.org/10.1016/0378-5173(91)90410-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Pathan, Aslam. "Stiripentol: New approved drug for the Dravet syndrome: Pharmacotherapeutics review." NeuroPharmac Journal 4, no. 1 (April 25, 2019): 94–98. http://dx.doi.org/10.37881/1.415.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Yıldız, Edibe Pembegul, Melis Ulak Ozkan, Tugce Aksu Uzunhan, Gonca Bektaş, Burak Tatlı, Nur Aydınlı, Mine Çalışkan, and Meral Özmen. "Efficacy of Stiripentol and the Clinical Outcome in Dravet Syndrome." Journal of Child Neurology 34, no. 1 (October 26, 2018): 33–37. http://dx.doi.org/10.1177/0883073818811538.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Chiron, Catherine. "Stiripentol for the treatment of seizures associated with Dravet syndrome." Expert Review of Neurotherapeutics 19, no. 4 (April 2, 2019): 301–10. http://dx.doi.org/10.1080/14737175.2019.1593142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Balestrini, S., and S. M. Sisodiya. "Audit of use of stiripentol in adults with Dravet syndrome." Acta Neurologica Scandinavica 135, no. 1 (May 27, 2016): 73–79. http://dx.doi.org/10.1111/ane.12611.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Le Dudal, Marine, Léa Huguet, Joëlle Perez, Sophie Vandermeersch, Elise Bouderlique, Ellie Tang, Carole Martori, et al. "Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning." Journal of Clinical Investigation 129, no. 6 (May 20, 2019): 2571–77. http://dx.doi.org/10.1172/jci99822.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Sada, N., S. Lee, T. Katsu, T. Otsuki, and T. Inoue. "Targeting LDH enzymes with a stiripentol analog to treat epilepsy." Science 347, no. 6228 (March 19, 2015): 1362–67. http://dx.doi.org/10.1126/science.aaa1299.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Stiripentol'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles